Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04900545

Enrollment

Registered

2021-05-25

Start date

2021-05-05

Completion date

2021-08-01

Last updated

2022-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Hypertension

Brief summary

Beta-blockers represent a cornerstone for the treatment of coronary artery disease (CAD). Their protective effect is based on the negative inotropic and chronotropic features, which have been tested in a large number of randomized controlled trials, both in patients with myocardial infarction (MI) and in those with stable angina, demonstrating a reduction of adverse cardiovascular events, a relief of symptoms and a reduction of myocardial ischemia However, considerable interpatient variability in response to β-blockers has been reported which indicates that a considerable proportion of β-blocker-treated patients do not achieve the warranted cardio protection with β- blockers. This highlights the importance of identifying biomarkers associated with variability in response to β-blockers to improve the current approach for β- blocker selection, which seems to be suboptimal. This study aims to study the effect of polymorphism in adrenergic beta receptors on beta-blocker response in Egyptian patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

1. Beta-blockers naïve patients 2. Patients been on beta-blocker therapy for at least 4 weeks. 3. Age (18-75) Years old.

Exclusion criteria

1. Non-Egyptians. 2. Kidney failure of any stage. 3. Liver failure of any stage. 4. Malignancy. 5. Pregnancy. 6. HR \< 55 beats/min (in the absence of b-blocker therapy). 7. Presence of a cardiac pacemaker.

Design outcomes

Primary

Measure	Time frame	Description
Adrenergic receptors genes and blood pressure response to beta-blocker	Three months	Investigate the association of the adrenergic receptor polymorphisms with reduction in blood pressure (expressed in units of millimeters of mercury mmHg ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy.
Adrenergic receptors genes and heart rate response to beta-blocker	Three months	Investigate the association of the adrenergic receptor polymorphisms with reduction in heart rate (expressed as beats per minute BPM ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy.

Countries

Egypt

Outcome results